JAK inhibitor in CALR-mutant myelofibrosis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

28 citing papers in PubMed.

1. Assessment of flonoltinib maleate versus ruxolitinib phosphate in intermediate- to high-risk myelofibrosis (FMF-02): study protocol for a multicenter, randomized, open-label phase IIB trial.Therapeutic advances in hematology · 2026
   Article
2. Challenges in the Evolving Role of Calreticulin as a Promising Target for Precision Medicine in Myeloproliferative Neoplasms.Cancers · 2025
   Review
3. The Role of Mutated Calreticulin in the Pathogenesis ofInternational journal of molecular sciences · 2024
   Article
4. Study of CALR, MPL, and c-kit Gene Mutations in Thai Patients with JAK2 V617F Negative Myeloproliferative Neoplasms.Asian Pacific journal of cancer prevention : APJCP · 2022
   Article
5. Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs.Blood advances · 2021
   Article
6. Myelofibrosis in 2019: moving beyond JAK2 inhibition.Blood cancer journal · 2019
   Review
7. Unfolding the Role of Calreticulin in Myeloproliferative Neoplasm Pathogenesis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019
   Review
8. The Calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera.Experimental hematology · 2017
   Article
9. Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition.Leukemia · 2017
   Review
10. Calreticulin: Challenges Posed by the Intrinsically Disordered Nature of Calreticulin to the Study of Its Function.Frontiers in cell and developmental biology · 2017
    Article
11. Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions.Hematology. American Society of Hematology. Education Program · 2016
    Review
12. Update from the latest WHO classification of MPNs: a user's manual.Hematology. American Society of Hematology. Education Program · 2016
    Review
13. Expression of CALR mutants causes mpl-dependent thrombocytosis in zebrafish.Blood cancer journal · 2016
    Article
14. Thrombopoietin receptor is required for the oncogenic function of CALR mutants.Leukemia · 2016
    Article
15. Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin.Leukemia · 2016
    Article
16. Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.Cancer discovery · 2016
    Article
17. Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned.OncoTargets and therapy · 2016
    Review
18. Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations.Current hematologic malignancy reports · 2015
    Review
19. JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice.Journal of cellular and molecular medicine · 2015
    Article
20. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.Journal of the National Comprehensive Cancer Network : JNCCN · 2015
    Review

Corrections and comments

• Commented on by
  JAK inhibitor in CALR-mutant myelofibrosis.2014
• Comment on
  Somatic mutations of calreticulin in myeloproliferative neoplasms.2013
• Comment on
  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.2013

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as